Initial public offering of Elekta (SE) — SEK 200 million Healthcare Initial public offering of Elekta (SE) — SEK 200 million
General advisory services in ProstaLund AB (SE) — SEK 100 million Healthcare General advisory services in ProstaLund AB (SE) — SEK 100 million
Rights issue in Medivir (SE) — SEK 225 million Healthcare Rights issue in Medivir (SE) — SEK 225 million
Directed new share issue in Active Biotech (SE) — SEK 375 million Healthcare Directed new share issue in Active Biotech (SE) — SEK 375 million
Rights issue in PA Resources (SE) — SEK 1.8 billion Oil & Gas Rights issue in PA Resources (SE) — SEK 1.8 billion
Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion Healthcare Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion
Acquisition of Fastighets AB Klövern (SE) by Wihlborgs Fastigheter AB (SE) — SEK 1.8 billion Real Estate Acquisition of Fastighets AB Klövern (SE) by Wihlborgs Fastigheter AB (SE) — SEK 1.8 billion
Divestment of Maersk Medical (DK) to Nordic Capital (SE) by A.P. Møller (DK) — Amount not disclosed. Healthcare Divestment of Maersk Medical (DK) to Nordic Capital (SE) by A.P. Møller (DK) — Amount not disclosed.
Bond issue in Kungsleden (SE) — SEK 600 million Real Estate Bond issue in Kungsleden (SE) — SEK 600 million
Divestment of Pharmadule Emtunga (SE) to 3i (UK) by Industrial Development & Investment AB ("IDI") (SE) — Amount not disclosed. Healthcare Divestment of Pharmadule Emtunga (SE) to 3i (UK) by Industrial Development & Investment AB ("IDI") (SE) — Amount not disclosed.
Directed issue of preference shares in Fastighets AB Balder (SE) — SEK 1 billion Real Estate Directed issue of preference shares in Fastighets AB Balder (SE) — SEK 1 billion